Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Eric Small, MD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1600 Divisadero St.
    San Francisco CA 94143
    Phone415-353-7095

       ORNG Applications 
       Websites
       In The News
       Awarded Grants
       Global Health
       More Info

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May 1; 12(5):686-718.
        View in: PubMed
      2. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May 1; 12(5):719-26.
        View in: PubMed
      3. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50.
        View in: PubMed
      4. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Mar 1; 32(7):671-7.
        View in: PubMed
      5. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 1; 11(12):1471-9.
        View in: PubMed
      6. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013 Nov 20; 105(22):1729-37.
        View in: PubMed
      7. Halabi S, Rini B, Escudier B, Stadler WM, Small EJ. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 1; 120(1):52-60.
        View in: PubMed
      8. Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013 Nov 1; 31(31):3944-50.
        View in: PubMed
      9. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14; 5(198):198ra108.
        View in: PubMed
      10. Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA. Reply to C.M. Booth et al. J Clin Oncol. 2013 Sep 10; 31(26):3300.
        View in: PubMed
      11. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43.
        View in: PubMed
      12. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013 Aug 1; 31(22):2791-8.
        View in: PubMed
      13. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 1; 11(5):594-615.
        View in: PubMed
      14. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4; 368(14):1314-25.
        View in: PubMed
      15. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 1; 11(4):446-75.
        View in: PubMed
      16. Cha E, Small EJ. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med. 2013 Apr; 2(2):243-52.
        View in: PubMed
      17. Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 3; 105(7):499-503.
        View in: PubMed
      18. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol. 2013 Mar 20; 31(9):1123-4.
        View in: PubMed
      19. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48.
        View in: PubMed
      20. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 1; 31(4):412-9.
        View in: PubMed
      21. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 1; 189(7):3759-66.
        View in: PubMed
      22. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9.
        View in: PubMed
      23. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1107-9; author reply 1109-12.
        View in: PubMed
      24. Bluestone JA, Small EJ. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8.
        View in: PubMed
      25. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 1; 30(13):1534-40.
        View in: PubMed
      26. Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 1; 118(17):4139-47.
        View in: PubMed
      27. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9.
        View in: PubMed
      28. Small EJ, de Bono JS. Prostate cancer: evolution or revolution? J Clin Oncol. 2011 Sep 20; 29(27):3595-8.
        View in: PubMed
      29. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 2011 Dec 15; 117(24):5579-88.
        View in: PubMed
      30. Small EJ, Penson DF, Sartor O. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Jul; 9(7 Suppl 13):1-15.
        View in: PubMed
      31. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61.
        View in: PubMed
      32. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
        View in: PubMed
      33. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer. 2011 Jun 1; 117(11):2419-25.
        View in: PubMed
      34. Stadler WM, Phillips G, George DJ, Halabi S, Small E. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694.
        View in: PubMed
      35. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
        View in: PubMed
      36. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 1; 117(3):526-33.
        View in: PubMed
      37. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22.
        View in: PubMed
      38. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov. 2010 Jul; 9(7):513-4.
        View in: PubMed
      39. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 1; 28(13):2137-43.
        View in: PubMed
      40. Harzstark AL, Small EJ. Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin Pharmacother. 2010 Apr; 11(6):937-45.
        View in: PubMed
      41. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40.
        View in: PubMed
      42. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8.
        View in: PubMed
      43. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010 Mar 20; 28(9):1489-95.
        View in: PubMed
      44. Small EJ, Fong L. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010 Mar 1; 28(7):1085-7.
        View in: PubMed
      45. Shah S, Small E. Emerging biological observations in prostate cancer. Expert Rev Anticancer Ther. 2010 Jan; 10(1):89-101.
        View in: PubMed
      46. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6.
        View in: PubMed
      47. Bajorin DF, Halabi S, Small E. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clin Genitourin Cancer. 2009 Oct; 7(3):E66-70.
        View in: PubMed
      48. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
        View in: PubMed
      49. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15; 115(16):3670-9.
        View in: PubMed
      50. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20; 27(15):2450-6.
        View in: PubMed
      51. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009 Jun 10; 27(17):2766-71.
        View in: PubMed
      52. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8.
        View in: PubMed
      53. Harzstark AL, Small EJ. Immunotherapeutics in development for prostate cancer. Oncologist. 2009 Apr; 14(4):391-8.
        View in: PubMed
      54. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009 Jun; 20(6):1074-9.
        View in: PubMed
      55. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
        View in: PubMed
      56. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7.
        View in: PubMed
      57. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39.
        View in: PubMed
      58. Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 1; 113(11):3137-45.
        View in: PubMed
      59. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8.
        View in: PubMed
      60. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10; 26(32):5275-83.
        View in: PubMed
      61. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol. 2008 Nov; 180(5):2011-7; discussion 2017-8.
        View in: PubMed
      62. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008 Sep 1; 113(5):975-84.
        View in: PubMed
      63. Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008 Sep; 6(2):110-6.
        View in: PubMed
      64. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep; 180(3):860-5; discussion 865-6.
        View in: PubMed
      65. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83.
        View in: PubMed
      66. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008 May 20; 26(15):2544-9.
        View in: PubMed
      67. Lin AM, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9.
        View in: PubMed
      68. Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 1; 72(3):814-9.
        View in: PubMed
      69. Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008 Apr; 44(4):271-8.
        View in: PubMed
      70. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1; 26(7):1148-59.
        View in: PubMed
      71. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May; 71(5):933-7.
        View in: PubMed
      72. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol. 2008 May; 19(5):946-50.
        View in: PubMed
      73. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008 Feb; 101(4):436-9.
        View in: PubMed
      74. D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008 May 1; 71(1):9-15.
        View in: PubMed
      75. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377.
        View in: PubMed
      76. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008 Jan; 101(1):20-5.
        View in: PubMed
      77. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer. 2007 Oct 1; 110(7):1478-84.
        View in: PubMed
      78. Lin AM, Small EJ. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91.
        View in: PubMed
      79. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007 Oct; 100(4):765-9.
        View in: PubMed
      80. Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007 Oct; 8(10):933-9.
        View in: PubMed
      81. Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther. 2007 Aug; 7(8):1275-80.
        View in: PubMed
      82. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 1; 110(3):556-63.
        View in: PubMed
      83. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul 1; 13(13):3883-91.
        View in: PubMed
      84. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8.
        View in: PubMed
      85. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007 May; 9(3):226-33.
        View in: PubMed
      86. Lin AM, Small EJ. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33.
        View in: PubMed
      87. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51.
        View in: PubMed
      88. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007 Apr 1; 13(7):2030-7.
        View in: PubMed
      89. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5.
        View in: PubMed
      90. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 2007 Mar; 99(3):519-24.
        View in: PubMed
      91. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol. 2007 Mar-Apr; 25(2):134-40.
        View in: PubMed
      92. Halabi S, Vogelzang NJ, Ou SS, Small EJ. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol. 2007 Feb; 177(2):531-4.
        View in: PubMed
      93. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54.
        View in: PubMed
      94. Kornblith AB, Dowell JM, Herndon JE, Engelman BJ, Bauer-Wu S, Small EJ, Morrison VA, Atkins J, Cohen HJ, Holland JC. Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. Cancer. 2006 Dec 1; 107(11):2706-14.
        View in: PubMed
      95. Ryan CJ, Small EJ. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol. 2006 Dec; 176(6 Pt 2):S61-5.
        View in: PubMed
      96. Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol. 2006 Dec; 176(6 Pt 2):S66-71.
        View in: PubMed
      97. Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):984-1014.
        View in: PubMed
      98. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9.
        View in: PubMed
      99. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9.
        View in: PubMed
      100. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006 Sep-Oct; 24(5):396-402.
        View in: PubMed
      101. Lin AM, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41.
        View in: PubMed
      102. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1163-7.
        View in: PubMed
      103. Ryan CJ, Small EJ. Androgen deprivation therapy in locally advanced and metastatic prostate cancer. Minerva Urol Nefrol. 2006 Sep; 58(3):119-26.
        View in: PubMed
      104. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20; 24(24):3984-90.
        View in: PubMed
      105. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006 Oct; 98(4):756-62.
        View in: PubMed
      106. Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol. 2006 Jul; 176(1):81-6.
        View in: PubMed
      107. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006 Jul; 12(7):778-85.
        View in: PubMed
      108. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1; 107(1):67-74.
        View in: PubMed
      109. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1; 24(19):3089-94.
        View in: PubMed
      110. Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 2):3596s-600s.
        View in: PubMed
      111. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 2006 Jun; 175(6):2087-91.
        View in: PubMed
      112. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17.
        View in: PubMed
      113. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006 May 1; 106(9):1917-24.
        View in: PubMed
      114. Lin AM, Rini BI, Small EJ. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10.
        View in: PubMed
      115. Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep. 2006 May; 7(3):239-46.
        View in: PubMed
      116. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3.
        View in: PubMed
      117. Ryan CJ, Small EJ. Prostate cancer update: 2005. Curr Opin Oncol. 2006 May; 18(3):284-8.
        View in: PubMed
      118. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21.
        View in: PubMed
      119. Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006 Mar; 4(4):269-74.
        View in: PubMed
      120. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006 Feb 1; 106(3):566-75.
        View in: PubMed
      121. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 1; 106(1):58-62.
        View in: PubMed
      122. Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13.
        View in: PubMed
      123. Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005 Nov 10; 23(32):8225-31.
        View in: PubMed
      124. Webster WS, Small EJ, Rini BI, Kwon ED. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol. 2005 Nov 10; 23(32):8262-9.
        View in: PubMed
      125. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer. 2005 Oct 15; 104(8):1627-32.
        View in: PubMed
      126. Garcia JA, Weinberg V, Small EJ. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):113-7.
        View in: PubMed
      127. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug; 66(2):386-91.
        View in: PubMed
      128. Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005 Jul 15; 11(14):5195-8.
        View in: PubMed
      129. Rosenberg JE, Carroll PR, Small EJ. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1):14-20.
        View in: PubMed
      130. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 1; 23(16):3726-32.
        View in: PubMed
      131. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005 Jun; 4(1):55-60.
        View in: PubMed
      132. Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005 May 15; 103(10):2035-41.
        View in: PubMed
      133. Ryan CJ, Small EJ. Progress in detection and treatment of prostate cancer. Curr Opin Oncol. 2005 May; 17(3):257-60.
        View in: PubMed
      134. Ryan CJ, Small EJ. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep. 2005 May; 7(3):228-33.
        View in: PubMed
      135. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 1; 23(13):2918-25.
        View in: PubMed
      136. Halabi S, Small EJ, Vogelzang NJ. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005 Apr 1; 23(10):2434-5; author reply 2435.
        View in: PubMed
      137. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005 Apr; 28(2):130-7.
        View in: PubMed
      138. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 1; 11(5):1815-20.
        View in: PubMed
      139. Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll PR, Chan JM. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):239-45.
        View in: PubMed
      140. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 1; 23(7):1439-46.
        View in: PubMed
      141. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer. 2005 Feb 1; 103(3):553-8.
        View in: PubMed
      142. Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine. 2005 Jan 21; 29(2):56-66.
        View in: PubMed
      143. Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jan; 3(1):4-5, 19-34.
        View in: PubMed
      144. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
        View in: PubMed
      145. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005 Feb 10; 23(5):1028-43.
        View in: PubMed
      146. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7; 351(15):1513-20.
        View in: PubMed
      147. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 1; 101(7):1569-74.
        View in: PubMed
      148. Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer. 2004 Sep; 3(2):122-4.
        View in: PubMed
      149. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004 Sep-Oct; 22(5):398-403.
        View in: PubMed
      150. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12.
        View in: PubMed
      151. Halabi S, Small EJ, Vogelzang NJ, Barrier RC, George SL, Gilligan TD. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 2004 Aug; 64(2):212-7.
        View in: PubMed
      152. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004 Jul 1; 101(1):90-5.
        View in: PubMed
      153. Rini BI, Weinberg V, Small EJ. Practice and progress in kidney cancer: methodology for novel drug development. J Urol. 2004 Jun; 171(6 Pt 1):2115-21.
        View in: PubMed
      154. Small EJ. Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol. 2004 Jul 1; 22(13):2515-6.
        View in: PubMed
      155. Ryan CJ, Small EJ. Advances in prostate cancer. Curr Opin Oncol. 2004 May; 16(3):242-6.
        View in: PubMed
      156. Ryan CJ, Small EJ. The selection of hormonal therapy in prostate cancer: who, when, and for how long? J Natl Compr Canc Netw. 2004 May; 2(3):261-8.
        View in: PubMed
      157. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6.
        View in: PubMed
      158. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15; 22(6):1025-33.
        View in: PubMed
      159. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer Res. 2004 Feb 15; 10(4):1219-25.
        View in: PubMed
      160. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 1; 22(3):537-56.
        View in: PubMed
      161. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:87-94.
        View in: PubMed
      162. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003 Dec 29; 62 Suppl 1:55-62.
        View in: PubMed
      163. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8.
        View in: PubMed
      164. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38.
        View in: PubMed
      165. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Dec 1; 21(23):4277-84.
        View in: PubMed
      166. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol. 2003 Oct; 30(5):649-58.
        View in: PubMed
      167. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8.
        View in: PubMed
      168. Rini BI, Small EJ. The potential for prostate cancer immunotherapy. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S117-25.
        View in: PubMed
      169. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun; 9(6):2040-8.
        View in: PubMed
      170. Rosenberg J, Small EJ. Prostate cancer update. Curr Opin Oncol. 2003 May; 15(3):217-21.
        View in: PubMed
      171. Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer. 2003 Apr 15; 97(8 Suppl):2090-8.
        View in: PubMed
      172. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003 Apr 1; 21(7):1232-7.
        View in: PubMed
      173. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003 Feb 1; 21(3):490-5.
        View in: PubMed
      174. Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003 Jan 1; 21(1):99-105.
        View in: PubMed
      175. Oh WK, Small EJ. Complementary and alternative therapies in prostate cancer. Semin Oncol. 2002 Dec; 29(6):575-84.
        View in: PubMed
      176. Bok RA, Small EJ. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer. 2002 Dec; 2(12):918-26.
        View in: PubMed
      177. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002 Oct 1; 20(19):3972-82.
        View in: PubMed
      178. Rini BI, Small EJ. Hormone-refractory Prostate Cancer. Curr Treat Options Oncol. 2002 Oct; 3(5):437-46.
        View in: PubMed
      179. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002 Sep 15; 20(18):3815-25.
        View in: PubMed
      180. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
        View in: PubMed
      181. Small EJ, Harris KA. Secondary hormonal manipulation of prostate cancer. Semin Urol Oncol. 2002 Aug; 20(3 Suppl 1):24-30.
        View in: PubMed
      182. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002 Aug; 168(2):542-5.
        View in: PubMed
      183. Meng MV, Grossfeld GD, Carroll PR, Small EJ. Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol. 2002 Aug; 20(3 Suppl 1):10-8.
        View in: PubMed
      184. Small EJ, Roach M. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002 Jun; 29(3):264-73.
        View in: PubMed
      185. Harris KA, Harney E, Small EJ. Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. Clin Prostate Cancer. 2002 Jun; 1(1):37-41.
        View in: PubMed
      186. Rini BI, Small EJ. Prostate cancer update. Curr Opin Oncol. 2002 May; 14(3):286-91.
        View in: PubMed
      187. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002 May; 167(5):1952-6.
        View in: PubMed
      188. Oh WK, Small EJ. PC-SPES and prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):59-66, viii.
        View in: PubMed
      189. Rini BI, Small EJ. Immunotherapy for prostate cancer. Curr Oncol Rep. 2001 Sep; 3(5):418-23.
        View in: PubMed
      190. Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001 Aug; 58(2 Suppl 1):56-64.
        View in: PubMed
      191. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 15):71-6.
        View in: PubMed
      192. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 2001 Aug; 58(2):240-5.
        View in: PubMed
      193. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 2001 Aug; 116(2):234-9.
        View in: PubMed
      194. Harris KA, Small EJ. Secondary hormonal manipulation of prostate cancer. Curr Urol Rep. 2001 Jun; 2(3):224-30.
        View in: PubMed
      195. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001 Mar 15; 61(6):2533-6.
        View in: PubMed
      196. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001 Mar 1; 19(5):1304-11.
        View in: PubMed
      197. Harris KA, Small EJ. Hormonal treatment for prostate cancer. Expert Opin Investig Drugs. 2001 Mar; 10(3):493-510.
        View in: PubMed
      198. Small EJ. Docetaxel in prostate cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S17-20.
        View in: PubMed
      199. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000 Dec 1; 18(23):3894-903.
        View in: PubMed
      200. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000 Nov 1; 18(21):3595-603.
        View in: PubMed
      201. Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000 Jul; 18(13):2537-44.
        View in: PubMed
      202. Grossfeld GD, Tigrani VS, Nudell D, Roach M, Weinberg VK, Presti JC, Small EJ, Carroll PR. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol. 2000 Jul; 164(1):93-9; discussion 100.
        View in: PubMed
      203. Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs. 2000 May; 18(2):193-7.
        View in: PubMed
      204. Small EJ, Reese DM. An update on prostate cancer research. Curr Opin Oncol. 2000 May; 12(3):265-72.
        View in: PubMed
      205. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000 Apr; 18(7):1440-50.
        View in: PubMed
      206. Reese DM, Corry M, Small EJ. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer. 2000 Mar 15; 88(6):1310-6.
        View in: PubMed
      207. Small EJ, Reese DM. New treatment strategies in advanced prostate cancer. Radiol Clin North Am. 2000 Jan; 38(1):203-11, ix-x.
        View in: PubMed
      208. Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology. 2000 Jan; 55(1):36-40.
        View in: PubMed
      209. Kashani-Sabet M, Sagebiel RW, Collins HE, Glassberg AB, Allen RE, Leong SP, Small EJ. Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial. Cancer. 1999 Nov 15; 86(10):2160-5.
        View in: PubMed
      210. Small EJ, Reese DM, Vogelzang NJ. Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol. 1999 Oct; 26(5 Suppl 17):61-7.
        View in: PubMed
      211. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999 Jul; 5(7):1738-44.
        View in: PubMed
      212. Small EJ. Advances in prostate cancer. Curr Opin Oncol. 1999 May; 11(3):226-35.
        View in: PubMed
      213. Bok RA, Small EJ. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999 May; 20(5):451-8.
        View in: PubMed
      214. Reese DM, Small EJ. Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am. 1999 May; 26(2):311-21, viii.
        View in: PubMed
      215. Coakley FV, Hricak H, Presti JC, Small EJ. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol. 1999 Apr; 72(856):412-3.
        View in: PubMed
      216. Frohlich MW, Small EJ. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am. 1998 Aug; 25(3):451-9.
        View in: PubMed
      217. Grossfeld GD, Small EJ. Long-term side effects of treatment for testis cancer. Urol Clin North Am. 1998 Aug; 25(3):503-15.
        View in: PubMed
      218. Small EJ. Prostate cancer, Incidence, management and outcomes. Drugs Aging. 1998 Jul; 13(1):71-81.
        View in: PubMed
      219. Small EJ. Update on the diagnosis and treatment of prostate cancer. Curr Opin Oncol. 1998 May; 10(3):244-52.
        View in: PubMed
      220. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am. 1998 May-Jun; 4(3):162-7.
        View in: PubMed
      221. Small EJ, Fippin LJ, Whisenant SP. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest. 1998; 16(7):456-61.
        View in: PubMed
      222. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998 Jan; 51(1):137-44.
        View in: PubMed
      223. Small EJ, Baron A, Bok R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997 Nov 1; 80(9):1755-9.
        View in: PubMed
      224. Small EJ. Prostate cancer. Curr Opin Oncol. 1997 May; 9(3):277-86.
        View in: PubMed
      225. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997 Apr; 157(4):1204-7.
        View in: PubMed
      226. Carroll PR, Presti JC, Small E, Roach M. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997 Mar; 49(3A Suppl):84-94.
        View in: PubMed
      227. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 Jan; 15(1):382-8.
        View in: PubMed
      228. Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. Cancer and Leukemia Group B trials for advanced prostate cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 14):28-31.
        View in: PubMed
      229. Roach M, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, Margolis LW, Presti J, Carroll PC, Phillips TL. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 1996 Nov; 156(5):1719-23.
        View in: PubMed
      230. Small EJ, Fippin LJ, Ernest ML, Carroll PR. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 1996 Oct 15; 78(8):1775-80.
        View in: PubMed
      231. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996 Jul 1; 56(13):3091-102.
        View in: PubMed
      232. Small EJ, Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995 Oct 15; 76(8):1428-34.
        View in: PubMed
      233. Timmerman JM, Northfelt DW, Small EJ. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol. 1995 Jun; 13(6):1391-7.
        View in: PubMed
      234. Small EJ, Frye JW, Wilkinson MJ, Carroll PR, Ernest ML, Stagg RJ. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer. 1994 Jun 1; 73(11):2803-7.
        View in: PubMed
      235. Small EJ, Carroll PR. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994 Mar; 43(3):408-10.
        View in: PubMed
      236. Wolf JS, Aronson FR, Small EJ, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol. 1994 Jan; 55(1):7-13.
        View in: PubMed
      237. Small EJ. Prostate cancer: who to screen, and what the results mean. Geriatrics. 1993 Dec; 48(12):28-30, 35-8.
        View in: PubMed
      238. Small EJ, Venook AP, Damon LE. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease. Cancer. 1993 Aug 1; 72(3):905-8.
        View in: PubMed
      239. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer. 1993 Jun 1; 71(11):3601-4.
        View in: PubMed
      Back to TOP